ChronoFlex C®️ with BioGUARD Technology

 

The FIRST and ONLY catheter proven to inhibit bacterial attachment1 (in vitro) AND to resist thrombus formation2 (in vivo) where it matters most.


Download GROUNDBREAKING study here

Coupled with over 35,000 catheter-days (and counting) of published data with ZERO BSIs and the highest completion of therapy (with less than 2% thrombosis ) compared to any catheter in its class…


 


 made of ChronoFlex C with BioGUARD Technology

Infection Prevention by Design.

 

BIOFILM LIFECYCLE

 

 

To understand the significance of BioGUARD Technology, let’s review the process of how bloodstream infections can occur:

 

 

Virtually ALL device-related bloodstream infections are

BIOFILM INFECTIONS 3

 

To help decrease the risk of a device-related bloodstream infection, it is vital to inhibit the attachment of bacteria and biofilm to the device.

INHIBITS BACTERIAL ATTACHMENT1

 

Standard polyurethane catheters have been shown to bloom additives to their surfaces during normal aging.

These surface additives are proven to “facilitate bacterial attachment”4,5a dangerous precursor to catheter-related bloodstream infections.

In contrast to standard polyurethane — ChronoFlex C with BioGUARD Technology removes dangerous surface additives and creates surface micro-texturing thereby inhibiting bacterial attachment1.

 

 

 

As shown above, Chronoflex C with BioGUARD technology showed a 70% reduction in bacteria and biofilm formation in comparison with a standard polyurethane catheter1.

AND the study found that even if bacteria did somehow find a way to attach to the POWERWAND catheter, they were 1.5 times more likely to die than when they attach to polyurethane1.

These findings help explain the superior clinical outcomes and ZERO CRBSIs already published with the POWERWAND (see below).

Peer-Reviewed Published Studies

Lead Author Institution Journal Associated BSI
Warrington Orlando Regional JAVA 2012 0.0%
Caparas NY Hosp. Queens JVascAcess 2014 0.0%
Sigl Advocate IL JAVA 2015 0.0%
Moreau Piedmont GA JAVA 2015 0.0%
Pathak Richmond NY Inf Dis Clin Practice 0.0%
Caparas New York Pres JAVA 2017 0.0%

Scientific Posters

Lead Author Institution Journal Associated BSI
Bird Texas Health AVA 2012 0.0%
Castro Las Palmas, TX AVA 2012 0.0%
Baliad Flagstaff Med Ctr. INS 2013 0.0%
Caparas NY Hosp. Queens INS 2013 0.0%
Robbins Brooke Army Hosp. AmBurnAssoc 2014 0.0%
DeVries Methodist Hosp. AVA 2017 0.0%

ChronoFlex C with BioGUARD is not a coating and not an embedded substance reducing risks associated with coatings and embedded additives:

 

  • Reduced risk of anaphylaxis
  • Reduced risk of bacterial resistance
  • Reduced risk of adverse material effects

Thromboresistant2

The POWERWAND is proven in vivo to resist thrombus formation with respect to thrombus on the surface of the catheter and thrombus on the wall of the vein, as compared with a commonly used control device2.

The formation of a thrombus on a catheter can lead to a deep-vein thrombosis (DVT). Similar to biofilm formation and bacterial attachment to the surface of a catheter, DVTs can increase the risk of catheter-related bloodstream infections6.

 

Reducing risk factors such as bacterial attachment and thrombus formation can significantly reduce the risk of CRBSIs.

 

When it comes to patient safety,

 

 

Infection Prevention by Design.

REFERENCES

1. Proven in vitro to significantly (p=0.0133) inhibit bacterial attachment and biofilm formation‡ as compared with a commonly used polyurethane catheter*

*PowerGlide (CR Bard, Salt Lake City, UT)

‡ Based on laboratory test results which may not be indicative of clinical results. Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection.

2. The POWERWAND is proven in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein. Based on canine jugular vein thromboresistance study, correlations to clinical applications has not been ascertained.

3. Hoiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, et. al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect 2015; 21:S1-S25.

4. Nouman M, Jubeli E, Saunier J, Yagoubi N. Exudation of additives to the surface of medical devices: impact on biocompatibility in the case of polyurethane used in implantable catheters. J Biomed Mater Res A. 2016;104(12):2954-2967.

5. Nouman M, Saunier J, Jubeli E, Yagoubi N. Additive blooming in polymer materials: Consequences in the pharmaceutical and medical field. Polymer Degradation and Stability. 2017;143:239-252.

6. Int J Clin Exp Med. 2014; 7(12): 5814–5819. Published online 2014 Dec 15.

† Data on file.